Kasturba hospital lab in Mumbai tested medical devices without license for 8 years: Maha FDA

Mumbai:  Kasturba Hospital’s laboratory was testing medical devices without a license for the past eight years, but has only now drawn action from the Food and Drug Administration (FDA).

FDA officials said an inspection of the hospital’s central analytical laboratory revealed that the facility continued to test products such as gauze, sutures, cotton and bandages without regulatory clearance even after new rules came into force in 2017. Until then, the lab held an umbrella license to test drugs and cosmetics, which also covered these devices.

These medical devices are supplied to BMC-run hospitals only after being tested for sterility, safety, and quality. While the hospital halted the activity in March, according to the FDA, it remains unclear whether alternative third-party testing was carried out, as hospital officials were unavailable for comment.

Nishigandha Pashte, a drug inspector with the FDA’s Zone 1, said, “When the rules changed, the hospital continued as before. They are now claiming they were unaware of the new regulations.”

The inspection was carried out with the Central Licensing Authority after complaints from one of the medical device suppliers. Pashte said Kasturba Hospital is now trying to restart the service by applying for a new license but is awaiting approval from its higher authorities.

Related Posts

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Food regulator FSSAI on Friday said it has suspended the licence of Punjab-based Rehaan Healthcare after it found serious violations of rules at the company’s health supplements and nutraceuticals manufacturing…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun